On the variability of HD 170699 - a possible COROT target

We present the analysis of the variability of HD 170699, a COROT star showing the characteristics of a non evolutionary Delta Scuti star with high rotational velocity. There is a clear period of 10.45 c/d with 5.29 mmag amplitude in the y filter. From the data, it can be seen that the star shows multi-periodicity and it is necessary to add more frequencies to adjust the observationsComment: To appear in RevMexAA(SC) in Proceedings of XII Reunion Regional Latinoamericana de la UAI held in Isla Margarita, Venezuela, October 22-26, 200

Quasinormal modes of massive charged flavor branes

We present an analysis and classification of vector and scalar fluctuations in a D3/D7 brane setup at finite termperature and baryon density. The system is dual to an N=2 supersymmetric Yang-Mills theory with SU(N_c) gauge group and N_f hypermultiplets in the fundamental representation in the quenched approximation. We improve significantly over previous results on the quasinormal mode spectrum of D7 branes and stress their novel physical interpretation. Amongst our findings is a new purely imaginary scalar mode that becomes tachyonic at sufficiently low temperature and baryon density. We establish the existence of a critical density above which the scalar mode stays in the stable regime for all temperatures. In the vector sector we study the crossover from the hydrodynamic to the quasiparticle regime and find that it moves to shorter wavelengths for lower temperatures. At zero baryon density the quasinormal modes move toward distinct discrete attractor frequencies that depend on the momentum as we increase the temperature. At finite baryon density, however, the trajectories show a turning behavior such that for low temperature the quasinormal mode spectrum approaches the spectrum of the supersymmetric zero temperature normal modes. We interpret this as resolution of the singular quasinormal mode spectrum that appears at the limiting D7 brane embedding at vanishing baryon density.Comment: 56 pages, 40 figure

Holographic Gravitational Anomaly and Chiral Vortical Effect

We analyze a holographic model with a pure gauge and a mixed gauge-gravitational Chern-Simons term in the action. These are the holographic implementations of the usual chiral and the mixed gauge-gravitational anomalies in four dimensional field theories with chiral fermions. We discuss the holographic renormalization and show that the gauge-gravitational Chern-Simons term does not induce new divergences. In order to cancel contributions from the extrinsic curvature at a boundary at finite distance a new type of counterterm has to be added however. This counterterm can also serve to make the Dirichlet problem well defined in case the gauge field strength vanishes on the boundary. A charged asymptotically AdS black hole is a solution to the theory and as an application we compute the chiral magnetic and chiral vortical conductivities via Kubo formulas. We find that the characteristic term proportional to T^2 is present also at strong coupling and that its numerical value is not renormalized compared to the weak coupling result.Comment: 27 pages, no figure

The CARMENES search for exoplanets around M dwarfs : stable radial-velocity variations at the rotation period of AD Leonis: A test case study of current limitations to treating stellar activity

Context. A challenge with radial-velocity (RV) data is disentangling the origin of signals either due to a planetary companion or to stellar activity. In fact, the existence of a planetary companion has been proposed, as well as contested, around the relatively bright, nearby M3.0 V star AD Leo at the same period as the stellar rotation of 2.23 days. Aims. We further investigate the nature of this signal. We introduce new CARMENES optical and near-IR RV data and an analysis in combination with archival data taken by HIRES and HARPS, along with more recent data from HARPS-N, GIANO-B, and HPF. Additionally, we address the confusion concerning the binarity of AD Leo. Methods. We consider possible correlations between the RVs and various stellar activity indicators accessible with CARMENES. We additionally applied models within a Bayesian framework to determine whether a Keplerian model, a red-noise quasi-periodic model using a Gaussian process, or a mixed model would explain the observed data best. We also exclusively focus on spectral lines potentially associated with stellar activity. Results. The CARMENES RV data agree with the previously reported periodicity of 2.23 days, correlate with some activity indicators, and exhibit chromaticity. However, when considering the entire RV data set, we find that a mixed model composed of a stable and a variable component performs best. Moreover, when recomputing the RVs using only spectral lines insensitive to activity, there appears to be some residual power at the period of interest. We therefore conclude that it is not possible to determinedly prove that there is no planet orbiting in synchronization with the stellar rotation given our data, current tools, machinery, and knowledge of how stellar activity affects RVs. We do rule out planets more massive than 27 M⊕ (=0.084 MJup). Likewise, we exclude any binary companion around AD Leo with M sin i greater than 3–6 MJup on orbital periods <14 yr

Assessment of a primary and tertiary care integrated management model for chronic obstructive pulmonary disease

<p>Abstract</p> <p>Background</p> <p>The diagnosis and treatment of patients with chronic obstructive pulmonary disease (COPD) in Spain continues to present challenges, and problems are exacerbated when there is a lack of coordinated follow-up between levels of care. This paper sets out the protocol for assessing the impact of an integrated management model for the care of patients with COPD. The new model will be evaluated in terms of 1) improvement in the rational utilization of health-care services and 2) benefits reflected in improved health status and quality of life for patients.</p> <p>Methods/Design</p> <p>A quasi-experimental study of the effectiveness of a COPD management model called COPD PROCESS. The patients in the study cohorts will be residents of neighborhoods served by two referral hospitals in Barcelona, Spain. One area comprises the intervention group (n = 32,248 patients) and the other the control group (n = 32,114 patients). The study will include pre- and post-intervention assessment 18 months after the program goes into effect. Analyses will be on two datasets: clinical and administrative data available for all patients, and clinical assessment information for a cohort of 440 patients sampled randomly from the intervention and control areas. The main endpoints will be the hospitalization rates in the two health-care areas and quality-of-life measures in the two cohorts.</p> <p>Discussion</p> <p>The COPD PROCESS model foresees the integrated multidisciplinary management of interventions at different levels of the health-care system through coordinated routine clinical practice. It will put into practice diagnostic and treatment procedures that are based on current evidence, multidisciplinary consensus, and efficient use of available resources. Care pathways in this model are defined in terms of patient characteristics, level of disease severity and the presence or absence of exacerbation. The protocol covers the full range of care from primary prevention to treatment of complex cases.</p

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

Background and purpose: Prospectively collected data comparing the safety and effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective was to directly compare the effectiveness and safety of NOACs in patients with newly diagnosed atrial fibrillation (AF). Methods: In GLORIA-AF, a large, prospective, global registry program, consecutive patients with newly diagnosed AF were followed for 3&nbsp;years. The comparative analyses for (1) dabigatran vs rivaroxaban or apixaban and (2) rivaroxaban vs apixaban were performed on propensity score (PS)-matched patient sets. Proportional hazards regression was used to estimate hazard ratios (HRs) for outcomes of interest. Results: The GLORIA-AF Phase III registry enrolled 21,300 patients between January 2014 and December 2016. Of these, 3839 were prescribed dabigatran, 4015 rivaroxaban and 4505 apixaban, with median ages of 71.0, 71.0, and 73.0&nbsp;years, respectively. In the PS-matched set, the adjusted HRs and 95% confidence intervals (CIs) for dabigatran vs rivaroxaban were, for stroke: 1.27 (0.79–2.03), major bleeding 0.59 (0.40–0.88), myocardial infarction 0.68 (0.40–1.16), and all-cause death 0.86 (0.67–1.10). For the comparison of dabigatran vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 1.16 (0.76–1.78), myocardial infarction 0.84 (0.48–1.46), major bleeding 0.98 (0.63–1.52) and all-cause death 1.01 (0.79–1.29). For the comparison of rivaroxaban vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 0.78 (0.52–1.19), myocardial infarction 0.96 (0.63–1.45), major bleeding 1.54 (1.14–2.08), and all-cause death 0.97 (0.80–1.19). Conclusions: Patients treated with dabigatran had a 41% lower risk of major bleeding compared with rivaroxaban, but similar risks of stroke, MI, and death. Relative to apixaban, patients treated with dabigatran had similar risks of stroke, major bleeding, MI, and death. Rivaroxaban relative to apixaban had increased risk for major bleeding, but similar risks for stroke, MI, and death. Registration: URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01468701, NCT01671007. Date of registration: September 2013